venture summit 2014, greg lucier
DESCRIPTION
TRANSCRIPT
![Page 1: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/1.jpg)
1
![Page 2: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/2.jpg)
2
![Page 3: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/3.jpg)
Moore’s Law
$3B
$4K
1999 20132005
Cost to
sequence
genome
Co
st
Pe
r G
en
om
eIn
form
atio
n V
alu
e
Genomic Sequencing: Unparalleled Productivity
3
![Page 4: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/4.jpg)
San Diego is at the Heart of Genomics
4
![Page 5: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/5.jpg)
Health Horizons Program. Institute for the Future. Top Ten Impediments to Better Health & Health Care in the United States. May 2005.
Error Rates in Healthcare Higher than Other Industries
5
![Page 6: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/6.jpg)
• The total addressable Genomics 2.0 app market is made up of both existing markets that could adopt new technologies as well as a number of new and emerging markets
Genomics 2.0 Potentially a US$23bn TAM
6
![Page 7: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/7.jpg)
7
![Page 8: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/8.jpg)
8
![Page 9: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/9.jpg)
9
![Page 10: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/10.jpg)
Wrong drug Selected,Find out
6 months later
The Cost Of A Wrong Answer
Note: metastatic basal cell carcinoma
10
![Page 11: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/11.jpg)
Oncology: Collision Course with Complexity
• 500+ compounds on the way
• Targeting more than 200 biomarkers
•Multiple Dx tests for each marker
11
![Page 12: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/12.jpg)
Cancer characterization has shifted from anatomic to genomic
12
![Page 13: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/13.jpg)
19th Century Personalized Medicine
13
![Page 14: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/14.jpg)
20th Century Personalized Medicine
14
![Page 15: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/15.jpg)
+ +
Changing Medicine Forever
Empiric Medicine
Evidence Based Medicine
Personalized (Sequencing)
Medicine
Real Personalized Medicine is here … TODAY
15
![Page 16: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/16.jpg)
My Interests in the Evolving Ecosystem
Enabling Technologies
Better Diagnostics & Monitoring
Treatment Delivery Frameworks
Drug Discovery & Development
16
![Page 17: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/17.jpg)
~$6M Saving Over 4 Yearsin Compute, Overhead, Networking & Storage costs for each HiSeq X Ten
To Analyze the Data Generated by One HiSeq X Ten
Takes Over 50 High End Compute Servers…
Or Just Accelerator Card1analyzes a whole human genome in 18 min
(A high end server takes 24 hours to do this!)
That is because…
Which provides…
17
![Page 18: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/18.jpg)
Epic Sciences – Technical Strengths and Applications
+CK-/CD45- (EMT cells)
Traditional CTC Process
Patient Sample
EpicProcess
Epithelial CTCs
Epithelial CTCs
Apoptotic CTCs
Small CTCs
• Unbiased approach, no enrichment
• See all CTC subtypes
• Subtypes confirmed by genomics
Recurrence Detection
Therapy Monitoring
Therapy Selection
ScreeningPhase I Phase II Phase III
CLINICAL TRIALS Patient Care
• Diagnostic assays for observational trials
• Diagnostic assays for patient selection in interventional trials
• On label, marketed CDx for therapy selection
• Novel independent diagnostics for therapy selection
• Real-time monitoring for drug resistance
“No Cell Left Behind” Application Areas
18
![Page 19: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/19.jpg)
RainTree – Creating Gold Standard Oncology Network
19
GPO / Distribution
Data(core analytics)
Care Management
Regional ACO’s
Orals, injectable, infusion
Pharmacy network
Pharma portal
Outcome analytics
Protocols
Best practices
Risk bearing
Multi-Billion Opportunity
![Page 20: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/20.jpg)
Source: NIH Office of the Director, Office of Budget
officeofbudget.od.nih.gov
NIH Appropriations in
Current and Constant Dollars
Pivoting to translational research and
partnerships to close NIH funding gap
• Implement 10-year strategic vision to ensure financial stability
• Leverage human biology and drug discovery expertise to accelerate therapeutics discovery
• Form clinical partnerships to advance patient-oriented research
• Partner with top-tier pharma/ biotech to diversify revenue
$0
$5,000,000,000
$10,000,000,000
$15,000,000,000
$20,000,000,000
$25,000,000,000
$30,000,000,000
$35,000,000,000
19951998
20012004
20072010
2013Constant $ (1995)Current $
20
![Page 21: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/21.jpg)
Building a Life Sciences Powerhouse
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
• 50 transaction
• 5000 patents
• $1.3 billion EBITDA
$3.96B
21
22% CAGR
$680M
![Page 22: Venture Summit 2014, Greg Lucier](https://reader033.vdocument.in/reader033/viewer/2022051609/5463c386af795983338b4643/html5/thumbnails/22.jpg)
A few thoughts on investing
• Look for ‘T’ Shaped Leaders
• The ‘weather’ is important, but so is the ‘climate’
• Get ahead of big ideas, but have the staying power to capture the value
• Have someone look over your shoulder to double-check your thesis
• Venture investing is full contact sport – you need to be in the huddle with the management team
22